Dexcom Inc. (NSDQ:DXCM) won FDA approval for next-generation continuous glucose monitor, news that preceded a nearly 7% drop in DXCM shares.
The San Diego, Calif.-based medical device company won U.S. market approval for its latest generation continuous glucose monitor, which represents "the most-advanced CGM system available," according to a company statement.